No significant weaknesses identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TECHBio-Techne Corporation | 10.9B | 69.96 | 152.09 | 5.23% | 6.41% | 3.97% | 2.35% | 0.23 |
| SPRYARS Pharmaceuticals, Inc. | 1.1B | 11.09 | 142.00 | 2970.63% | -56.06% | -54.21% | 1.18% | 0.00 |
| VCYTVeracyte, Inc. | 3.24B | 41.00 | 132.26 | 23.46% | 6.12% | 2.41% | 1.97% | 0.04 |
| CSBRChampions Oncology, Inc. | 99.56M | 7.17 | 21.73 | 13.54% | 4.32% | 59.65% | 7.03% | 1.62 |
| MDXGMiMedx Group, Inc. | 851.59M | 5.75 | 20.54 | 8.52% | 10.38% | 17.09% | 7.58% | 0.13 |
| LTRNLantern Pharma Inc. | 39.26M | 3.51 | -0.00 | -197.36% | 0.01 | |||
| SEERSeer, Inc. | 107.44M | 1.91 | -1.37 | -8.13% | -486.02% | -29.19% | 0.08 | |
| IMDXInsight Molecular Diagnostics Inc. | 189.76M | 6.62 | -1.42 | 25.15% | -13.81% | -14.81% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 49.5M | 65.08M | 71.95M | 92.01M | 120.37M | 117.48M | 219.51M | 296.54M | 361.05M | 445.76M |
| Revenue Growth % | 0.3% | 0.31% | 0.11% | 0.28% | 0.31% | -0.02% | 0.87% | 0.35% | 0.22% | 0.23% |
| Cost of Goods Sold | 21.5M | 25.46M | 28.2M | 33.08M | 36.52M | 41.45M | 74.4M | 101.58M | 112.9M | 147.62M |
| COGS % of Revenue | 0.43% | 0.39% | 0.39% | 0.36% | 0.3% | 0.35% | 0.34% | 0.34% | 0.31% | 0.33% |
| Gross Profit | 28.01M | 39.62M | 43.76M | 58.93M | 83.84M | 76.03M | 145.11M | 194.95M | 248.15M | 298.14M |
| Gross Margin % | 0.57% | 0.61% | 0.61% | 0.64% | 0.7% | 0.65% | 0.66% | 0.66% | 0.69% | 0.67% |
| Gross Profit Growth % | 0.3% | 0.41% | 0.1% | 0.35% | 0.42% | -0.09% | 0.91% | 0.34% | 0.27% | 0.2% |
| Operating Expenses | 61.47M | 68.43M | 70.3M | 81.16M | 98.97M | 111.42M | 227.02M | 236.03M | 333.94M | 282M |
| OpEx % of Revenue | 1.24% | 1.05% | 0.98% | 0.88% | 0.82% | 0.95% | 1.03% | 0.8% | 0.92% | 0.63% |
| Selling, General & Admin | 47.88M | 52.03M | 55.35M | 65.28M | 82.72M | 89.12M | 181.19M | 174.08M | 184.23M | 206.04M |
| SG&A % of Revenue | 0.97% | 0.8% | 0.77% | 0.71% | 0.69% | 0.76% | 0.83% | 0.59% | 0.51% | 0.46% |
| Research & Development | 12.8M | 15.32M | 13.88M | 14.82M | 14.85M | 17.2M | 29.84M | 40.6M | 57.3M | 69.29M |
| R&D % of Revenue | 0.26% | 0.24% | 0.19% | 0.16% | 0.12% | 0.15% | 0.14% | 0.14% | 0.16% | 0.16% |
| Other Operating Expenses | 140K | 202K | 476K | 1.2M | 1.4M | 5.09M | 15.98M | 21.35M | 92.41M | 6.67M |
| Operating Income | -33.47M | -28.8M | -26.54M | -22.23M | -15.13M | -35.39M | -81.9M | -41.08M | -85.8M | 16.14M |
| Operating Margin % | -0.68% | -0.44% | -0.37% | -0.24% | -0.13% | -0.3% | -0.37% | -0.14% | -0.24% | 0.04% |
| Operating Income Growth % | -0.15% | 0.14% | 0.08% | 0.16% | 0.32% | -1.34% | -1.31% | 0.5% | -1.09% | 1.19% |
| EBITDA | -32.67M | -25.29M | -22.7M | -18.31M | -11.01M | -27.45M | -60.68M | -11.83M | -58.61M | 39.6M |
| EBITDA Margin % | -0.66% | -0.39% | -0.32% | -0.2% | -0.09% | -0.23% | -0.28% | -0.04% | -0.16% | 0.09% |
| EBITDA Growth % | -0.17% | 0.23% | 0.1% | 0.19% | 0.4% | -1.49% | -1.21% | 0.8% | -3.95% | 1.68% |
| D&A (Non-Cash Add-back) | 800K | 3.51M | 3.84M | 3.92M | 4.12M | 7.94M | 21.23M | 29.25M | 27.19M | 23.46M |
| EBIT | -33.33M | -28.65M | -27.6M | -21.04M | -11.92M | -34.68M | -81.41M | -36.23M | -76.6M | 25.75M |
| Net Interest Income | -378K | -2.76M | -4.94M | -1.96M | 2.35M | 365K | -106K | 1.77M | 7.33M | 11.15M |
| Interest Income | 0 | 0 | 0 | 0 | 3.02M | 594K | 135K | 1.97M | 7.34M | 11.15M |
| Interest Expense | 378K | 2.76M | 4.94M | 1.96M | 677K | 229K | 241K | 198K | 15K | 2K |
| Other Income/Expense | -238K | -2.56M | -4.46M | -766K | 2.53M | 480K | 254K | 4.65M | 9.18M | 9.6M |
| Pretax Income | -33.7M | -31.36M | -31M | -23M | -12.6M | -34.91M | -81.65M | -36.43M | -76.61M | 25.74M |
| Pretax Margin % | -0.68% | -0.48% | -0.43% | -0.25% | -0.1% | -0.3% | -0.37% | -0.12% | -0.21% | 0.06% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -6.09M | 133K | -2.21M | 1.61M |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 0.93% | 1% | 0.97% | 0.94% |
| Net Income | -33.7M | -31.36M | -31M | -23M | -12.6M | -34.91M | -75.56M | -36.56M | -74.4M | 24.14M |
| Net Margin % | -0.68% | -0.48% | -0.43% | -0.25% | -0.1% | -0.3% | -0.34% | -0.12% | -0.21% | 0.05% |
| Net Income Growth % | -0.15% | 0.07% | 0.01% | 0.26% | 0.45% | -1.77% | -1.16% | 0.52% | -1.04% | 1.32% |
| Net Income (Continuing) | -33.7M | -31.36M | -31M | -23M | -12.6M | -34.91M | -75.56M | -36.56M | -74.4M | 24.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.30 | -1.09 | -0.91 | -0.62 | -0.27 | -0.66 | -1.11 | -0.51 | -1.02 | 0.31 |
| EPS Growth % | 0.04% | 0.16% | 0.17% | 0.32% | 0.56% | -1.44% | -0.68% | 0.54% | -1% | 1.3% |
| EPS (Basic) | -1.30 | -1.09 | -0.91 | -0.62 | -0.27 | -0.66 | -1.11 | -0.51 | -1.02 | 0.32 |
| Diluted Shares Outstanding | 25.94M | 28.83M | 33.93M | 37.02M | 46.14M | 53.24M | 67.89M | 71.55M | 72.64M | 78.16M |
| Basic Shares Outstanding | 25.94M | 28.83M | 33.93M | 37.02M | 46.14M | 53.24M | 67.89M | 71.55M | 72.64M | 76.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 47.93M | 73.63M | 53.93M | 96.95M | 187.69M | 375.68M | 243.1M | 248.64M | 285.62M | 372.27M |
| Cash & Short-Term Investments | 39.08M | 59.22M | 33.89M | 78M | 159.32M | 349.36M | 177.16M | 178.85M | 216.45M | 289.44M |
| Cash Only | 39.08M | 59.22M | 33.89M | 78M | 159.32M | 349.36M | 173.2M | 154.25M | 216.45M | 239.09M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 3.96M | 24.61M | 0 | 50.35M |
| Accounts Receivable | 3.5M | 8.76M | 12.72M | 13.17M | 19.33M | 18.46M | 41.46M | 44.02M | 40.38M | 46.52M |
| Days Sales Outstanding | 25.83 | 49.1 | 64.51 | 52.24 | 58.61 | 57.36 | 68.94 | 54.18 | 40.82 | 38.1 |
| Inventory | 3.77M | 3.48M | 5.32M | 3.4M | 6.81M | 4.66M | 11.22M | 14.29M | 16.13M | 21.75M |
| Days Inventory Outstanding | 63.96 | 49.81 | 68.92 | 37.54 | 68.02 | 41 | 55.07 | 51.36 | 52.14 | 53.78 |
| Other Current Assets | 118K | 320K | 2M | 0 | 0 | 0 | -3.96M | 11.47M | 12.66M | 14.55M |
| Total Non-Current Assets | 27.35M | 27.41M | 24.74M | 23.69M | 87.53M | 81.48M | 944.72M | 907.79M | 829.28M | 927.77M |
| Property, Plant & Equipment | 10.31M | 11.48M | 9.69M | 8.94M | 17.74M | 16.83M | 31.14M | 30.86M | 30.86M | 71.14M |
| Fixed Asset Turnover | 4.80x | 5.67x | 7.43x | 10.29x | 6.78x | 6.98x | 7.05x | 9.61x | 11.70x | 6.27x |
| Goodwill | 1.06M | 1.06M | 1.06M | 1.06M | 2.73M | 2.73M | 707.9M | 695.89M | 702.98M | 745.8M |
| Intangible Assets | 15.2M | 14.13M | 13.07M | 12M | 65.02M | 59.92M | 202.73M | 174.87M | 88.59M | 102.3M |
| Long-Term Investments | 603K | 603K | 603K | 603K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 781K | 737K | 929K | 1.69M | 2.04M | 2M | 2.95M | 6.17M | 6.85M | 8.53M |
| Total Assets | 75.28M | 101.03M | 78.67M | 120.64M | 275.21M | 457.16M | 1.19B | 1.16B | 1.11B | 1.3B |
| Asset Turnover | 0.66x | 0.64x | 0.91x | 0.76x | 0.44x | 0.26x | 0.18x | 0.26x | 0.32x | 0.34x |
| Asset Growth % | 0.16% | 0.34% | -0.22% | 0.53% | 1.28% | 0.66% | 1.6% | -0.03% | -0.04% | 0.17% |
| Total Current Liabilities | 14.72M | 11.53M | 12.03M | 13.06M | 17.47M | 16.78M | 64.15M | 62.61M | 61.24M | 78.63M |
| Accounts Payable | 5.08M | 2.42M | 3.85M | 2.52M | 2.33M | 3.12M | 12.36M | 11.91M | 12.94M | 8.63M |
| Days Payables Outstanding | 86.34 | 34.75 | 49.88 | 27.76 | 23.27 | 27.44 | 60.64 | 42.8 | 41.84 | 21.35 |
| Short-Term Debt | 0 | 0 | 0 | 1.36M | 0 | 0 | 1.13M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 948K | 0 | 0 | 0 | 0 | 371K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 948K | 0 | 0 | 0 | 10.1M | 9.2M | 33.7M | 36.88M | 29.19M | 47.59M |
| Current Ratio | 3.26x | 6.38x | 4.48x | 7.42x | 10.74x | 22.39x | 3.79x | 3.97x | 4.66x | 4.73x |
| Quick Ratio | 3.00x | 6.08x | 4.04x | 7.16x | 10.35x | 22.11x | 3.61x | 3.74x | 4.40x | 4.46x |
| Cash Conversion Cycle | 3.45 | 64.17 | 83.55 | 62.01 | 103.36 | 70.92 | 63.37 | 62.75 | 51.12 | 70.53 |
| Total Non-Current Liabilities | 9.31M | 29.92M | 29.42M | 27.82M | 18.29M | 19.15M | 27.16M | 18.61M | 9.56M | 45.44M |
| Long-Term Debt | 4.99M | 24.92M | 24.94M | 23.93M | 694K | 810K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 599K | 308K | 0 | 11.51M | 9.92M | 14.1M | 10.65M | 7.53M | 43.24M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 5.59M | 4.53M | 734K | 1.23M |
| Other Non-Current Liabilities | 4.28M | 4.4M | 4.17M | 3.9M | 6.09M | 7.59M | 7.13M | 3.43M | 1.3M | 972K |
| Total Liabilities | 24.03M | 41.45M | 41.44M | 40.88M | 35.76M | 35.93M | 91.31M | 81.22M | 70.8M | 124.07M |
| Total Debt | 5.03M | 25.52M | 25.25M | 25.28M | 13.61M | 12.32M | 18.85M | 14.72M | 12.63M | 50.74M |
| Net Debt | -34.06M | -33.7M | -8.64M | -52.71M | -145.71M | -337.05M | -154.34M | -139.53M | -203.82M | -188.35M |
| Debt / Equity | 0.10x | 0.43x | 0.68x | 0.32x | 0.06x | 0.03x | 0.02x | 0.01x | 0.01x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.28x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -4.76x |
| Interest Coverage | -88.53x | -10.45x | -5.37x | -11.33x | -22.34x | -154.54x | -339.85x | -207.48x | -5719.67x | 8071.00x |
| Total Equity | 51.25M | 59.58M | 37.23M | 79.75M | 239.46M | 421.23M | 1.1B | 1.08B | 1.04B | 1.18B |
| Equity Growth % | 0.24% | 0.16% | -0.38% | 1.14% | 2% | 0.76% | 1.6% | -0.02% | -0.03% | 0.13% |
| Book Value per Share | 1.98 | 2.07 | 1.10 | 2.15 | 5.19 | 7.91 | 16.15 | 15.03 | 14.37 | 15.05 |
| Total Shareholders' Equity | 51.25M | 59.58M | 37.23M | 79.75M | 239.46M | 421.23M | 1.1B | 1.08B | 1.04B | 1.18B |
| Common Stock | 28K | 34K | 34K | 41K | 50K | 58K | 71K | 72K | 73K | 78K |
| Retained Earnings | -148.73M | -180.08M | -211.09M | -234.09M | -246.69M | -281.59M | -357.16M | -393.72M | -468.12M | -443.98M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5.44M | -6.84M | -9.3M | -12.01M | 0 | 0 | -15.08M | -31.35M | -24.02M | -36.09M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -26.96M | -27.98M | -23.91M | -13.52M | -3.23M | -9.71M | -31.62M | 7.54M | 44.22M | 75.1M |
| Operating CF Margin % | -0.54% | -0.43% | -0.33% | -0.15% | -0.03% | -0.08% | -0.14% | 0.03% | 0.12% | 0.17% |
| Operating CF Growth % | 0.02% | -0.04% | 0.15% | 0.43% | 0.76% | -2% | -2.26% | 1.24% | 4.87% | 0.7% |
| Net Income | -33.7M | -31.36M | -31M | -23M | -12.6M | -34.91M | -75.56M | -36.56M | -74.4M | 24.14M |
| Depreciation & Amortization | 2.25M | 3.51M | 3.84M | 3.92M | 4.12M | 7.94M | 19.59M | 25.93M | 27.19M | 23.46M |
| Stock-Based Compensation | 5.6M | 6.38M | 6.62M | 5.96M | 9.81M | 12.99M | 22.52M | 26.73M | 33.14M | 36.25M |
| Deferred Taxes | 105K | 80K | 12K | 0 | -23K | 0 | -6.26M | 133K | -3.84M | -233K |
| Other Non-Cash Items | -1.77M | -184K | 2.06M | 251K | 312K | 4.74M | 3.87M | 7.68M | 66.3M | 12.8M |
| Working Capital Changes | 550K | -6.41M | -5.44M | -651K | -4.85M | -481K | 4.22M | -16.38M | -4.16M | -21.32M |
| Change in Receivables | -558K | -5.32M | -3.96M | -452K | -6.16M | 955K | -8.57M | -4.5M | 3.89M | -6.41M |
| Change in Inventory | -71K | 292K | -1.85M | 1.92M | -3.4M | 1.06M | -1.46M | -3.01M | -1.69M | -5.87M |
| Change in Payables | -3.55M | -1.44M | 1.73M | -1.57M | -141K | 711K | 5.16M | 152K | -134K | -4.3M |
| Cash from Investing | -6.7M | -4.21M | -1.2M | -1.87M | -42.73M | -3.84M | -739.21M | -29.39M | 15.11M | -56.27M |
| Capital Expenditures | -6.17M | -4.21M | -1.75M | -1.87M | -2.76M | -2.84M | -5.38M | -8.55M | -9.96M | -11.29M |
| CapEx % of Revenue | 0.12% | 0.06% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.03% | 0.03% | 0.03% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -533K | -2K | 560K | 0 | 23K | 0 | -162.42M | 0 | 0 | 0 |
| Cash from Financing | 37.73M | 52.33M | -218K | 59.5M | 127.29M | 203.59M | 596.32M | 3.49M | 2.84M | 4.9M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 475K | 1.22M | 1.9M | 4.75M | 14.65M | 9.86M | 2.5M | 4.78M | 2.84M | -15.09M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -33.13M | -32.19M | -25.67M | -15.39M | -5.99M | -12.55M | -37M | -1.01M | 34.26M | 63.81M |
| FCF Margin % | -0.67% | -0.49% | -0.36% | -0.17% | -0.05% | -0.11% | -0.17% | -0% | 0.09% | 0.14% |
| FCF Growth % | -0.12% | 0.03% | 0.2% | 0.4% | 0.61% | -1.1% | -1.95% | 0.97% | 34.79% | 0.86% |
| FCF per Share | -1.28 | -1.12 | -0.76 | -0.42 | -0.13 | -0.24 | -0.54 | -0.01 | 0.47 | 0.82 |
| FCF Conversion (FCF/Net Income) | 0.80x | 0.89x | 0.77x | 0.59x | 0.26x | 0.28x | 0.42x | -0.21x | -0.59x | 3.11x |
| Interest Paid | 278K | 2.15M | 2.72M | 1.55M | 332K | 13K | 9K | 9K | 0 | 0 |
| Taxes Paid | 22K | 7K | 21K | 79K | 35K | 112K | 112K | 570K | 1.7M | 2.24M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -72.77% | -56.59% | -64.05% | -39.32% | -7.89% | -10.57% | -9.96% | -3.37% | -7.02% | 2.17% |
| Return on Invested Capital (ROIC) | -176.27% | -100.3% | -73.1% | -59.96% | -18.79% | -29.83% | -11.97% | -3.28% | -7.25% | 1.32% |
| Gross Margin | 56.57% | 60.88% | 60.81% | 64.05% | 69.66% | 64.71% | 66.11% | 65.74% | 68.73% | 66.88% |
| Net Margin | -68.08% | -48.18% | -43.09% | -25% | -10.47% | -29.71% | -34.42% | -12.33% | -20.61% | 5.42% |
| Debt / Equity | 0.10x | 0.43x | 0.68x | 0.32x | 0.06x | 0.03x | 0.02x | 0.01x | 0.01x | 0.04x |
| Interest Coverage | -88.53x | -10.45x | -5.37x | -11.33x | -22.34x | -154.54x | -339.85x | -207.48x | -5719.67x | 8071.00x |
| FCF Conversion | 0.80x | 0.89x | 0.77x | 0.59x | 0.26x | 0.28x | 0.42x | -0.21x | -0.59x | 3.11x |
| Revenue Growth | 29.62% | 31.48% | 10.55% | 27.87% | 30.82% | -2.4% | 86.85% | 35.09% | 21.76% | 23.46% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Testing | - | 107.36M | 101.97M | 58.86M | 250.54M | 326.54M | 418.96M |
| Testing Growth | - | - | -5.02% | -42.28% | 325.66% | 30.33% | 28.30% |
| Product | - | 923K | 9.85M | - | 12.63M | 15.59M | 13.65M |
| Product Growth | - | - | 966.63% | - | - | 23.40% | -12.43% |
| Biopharmaceutical And Other | - | - | - | 19.87M | 33.36M | 18.92M | 13.15M |
| Biopharmaceutical And Other Growth | - | - | - | - | 67.91% | -43.28% | -30.48% |
| Biopharmaceutical | - | 8.09M | 5.67M | - | - | - | - |
| Biopharmaceutical Growth | - | - | -29.94% | - | - | - | - |
| Collaboration | - | 4M | - | - | - | - | - |
| Collaboration Growth | - | - | - | - | - | - | - |
| Provision of Data | - | 7M | - | - | - | - | - |
| Provision of Data Growth | - | - | - | - | - | - | - |
| Fulfillment of Obligations | - | 4M | - | - | - | - | - |
| Fulfillment of Obligations Growth | - | - | - | - | - | - | - |
| Service | 250K | 250K | - | - | - | - | - |
| Service Growth | - | 0.00% | - | - | - | - | - |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| UNITED STATES | - | - | 109.61M | 200.98M | 262.92M | 334.52M | 423.54M |
| UNITED STATES Growth | - | - | - | 83.35% | 30.82% | 27.23% | 26.61% |
| Non-US | - | - | 7.87M | 18.53M | 33.61M | 26.53M | 22.23M |
| Non-US Growth | - | - | - | 135.51% | 81.38% | -21.08% | -16.21% |
Veracyte, Inc. (VCYT) has a price-to-earnings (P/E) ratio of 132.3x. This suggests investors expect higher future growth.
Veracyte, Inc. (VCYT) reported $495.1M in revenue for fiscal year 2024. This represents a 18620% increase from $2.6M in 2011.
Veracyte, Inc. (VCYT) grew revenue by 23.5% over the past year. This is strong growth.
Yes, Veracyte, Inc. (VCYT) is profitable, generating $30.3M in net income for fiscal year 2024 (5.4% net margin).
Veracyte, Inc. (VCYT) has a return on equity (ROE) of 2.2%. This is below average, suggesting room for improvement.
Veracyte, Inc. (VCYT) generated $98.2M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.